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An excess of iron resulting from regular blood transfu-
sion therapy leads to the appearance of non-transferrin-
bound iron (NTBI) in the blood (1). The appearance of
NTBI has been hypothesized to increase the risk for
developing co-morbidities (2). Labile plasma iron (LPI),
a directly chelatable form of NTBI, is readily taken up
by cells leading to expansion of the cellular iron pool. As
LPI is produced continually in conditions of iron over-
load, the sustained presence of an iron chelator in the
plasma may help avoid accumulation of excess iron,
thereby preventing iron-related morbidity and mortality.
A limitation of both deferoxamine (DFO) and deferi-
prone monotherapy is an inability to constantly control
levels of LPI (3) because of their short plasma half-lives
(4, 5).
Because of to its long half-life of 8–16 h (6, 7), thera-
peutic levels of the oral chelator deferasirox (Exjade ;
Novartis Pharma AG, Basel, Switzerland) are present in
the plasma for 24 h following once-daily administration
(6). The ESCALATOR trial was initiated to evaluate the
efﬁcacy and safety of deferasirox in regularly transfused
patients with b-thalassaemia who had previously received
chelation therapy with DFO and⁄or deferiprone. We
report here the results of a subgroup analysis examining
the effect of deferasirox on LPI levels in a subgroup of
patients from a single centre of the ESCALATOR study.
Abstract
This subgroup analysis evaluated the effect of once-daily oral deferasirox on labile plasma iron (LPI) levels
in patients from the prospective, 1-yr, multicentre ESCALATOR study. Mean baseline liver iron concentra-
tion and median serum ferritin levels were 28.6 ± 10.3 mg Fe⁄g dry weight and 6334 ng⁄mL respectively,
indicating high iron burden despite prior chelation therapy. Baseline LPI levels (0.98 ± 0.82 lmol⁄L)
decreased signiﬁcantly to 0.12 ± 0.16 lmol⁄L, 2 h after ﬁrst deferasirox dose (P = 0.0006). Reductions
from pre- to post-deferasirox administration were also observed at all other time points. Compared to
baseline, there was a signiﬁcant reduction in preadministration LPI that reached the normal range at week
4 and throughout the remainder of the study (P £ 0.02). Pharmacokinetic analysis demonstrated an inverse
relationship between preadministration LPI levels and trough deferasirox plasma concentrations. Once-daily
dosing with deferasirox ‡20 mg⁄kg⁄d provided sustained reduction in LPI levels in these heavily iron-over-
loaded patients, suggesting 24-h protection from LPI. Deferasirox may therefore reduce unregulated tissue
iron loading and prevent further end-organ damage.
Key words deferasirox; oral; b-thalassaemia; labile plasma iron; pharmacokinetic
Correspondence Shahina Daar, Department of Hematology, College of Medicine, Sultan Qaboos University, P.O. Box 35, Muscat
123, Oman. Tel: +968 99410996; Fax: +968 24413419; e-mail: asdoc@omantel.net.om
Accepted for publication 18 December 2008 doi:10.1111/j.1600-0609.2008.01204.x
Re-use of this article is permitted in accordance with the
Creative Commons Deed, Attribution 2.5, which does
not permit commercial exploitation.
ORIGINAL ARTICLE
European Journal of Haematology ISSN 0902-4441
454
ª 2009 The Authors
Journal compilation 82 (454–457) ª 2009 Blackwell MunksgaardPatients and methods
Study design
The ESCALATOR trial was a prospective, open-label, 1-
yr, multicentre study conducted in the Middle East.
Enrolled patients were males or females aged ‡2 yr with
b-thalassaemia. All had transfusional iron overload, as
indicated by a liver iron concentration (LIC) ‡2m gF e⁄g
dry weight (dw) and serum ferritin levels ‡500 ng⁄mL, ala-
nine aminotransferase levels <300 U⁄L and normal renal
function at baseline. In addition, all patients had been pre-
viously chelated with monotherapy or combination ther-
apy with DFO and⁄or deferiprone, but chelation was
considered unsuccessful because of unacceptable toxicity,
contraindication, poor response despite proper compli-
ance or documented non-compliance of taking <50% of
prescribed doses in the previous year. Patients who previ-
ously received deferiprone discontinued treatment at least
28 d before they received the ﬁrst dose of deferasirox.
Patients were permitted to receive DFO until the day
before they initiated deferasirox therapy. Institutional
Review Board or Ethics Committee approval was
obtained at each participating institution and all patients
(or parents⁄guardians) provided written informed consent.
The study was conducted in accordance with Good Clini-
cal Practice guidelines and the Declaration of Helsinki.
All patients included in this analysis received a starting
dose of deferasirox 20 mg⁄kg⁄d, administered orally once
daily. Routine dose adjustments, in steps of 5 or
10 mg⁄kg⁄d within a range of 0–30 mg⁄kg⁄d, were made
according to serum ferritin trends and safety markers.
LPI was assessed in a subgroup of 14 patients, all
enrolled at a single centre in Oman. Further details of
study design and the efﬁcacy and safety results from the
full study population have been reported separately
(A. Taher, A. El-Beshlawy, M.S. Elalfy, K. Al Zir,
S. Daar, G. Damanhouri, D Habr, U. Kriemler-Krahn,
A. Hmissi, A. Al Jefri, unpublished data).
Assessments
Blood samples for LPI assessment were taken preadmin-
istration (i.e. the predicted LPI daily peak) and 2 h post-
administration (i.e. the predicted daily LPI nadir and
approximately equivalent to the time of maximum defer-
asirox plasma concentration) at baseline (prior to the
ﬁrst deferasirox dose) and following uninterrupted daily
administration at weeks 4, 16, 28, 40 and 52. Additional
blood samples were taken to evaluate trough and peak
plasma concentrations of deferasirox and the deferasi-
rox–iron chelate complex.
LPI levels were analyzed according to the method
deﬁned by Esposito (8), using an assay that measures
iron-speciﬁc redox cycling capacity in the presence of
low ascorbate concentrations. Redox reactions were
detected by the oxidation of a ﬂuorogenic probe to its
ﬂuorescent form. This method allowed distinction of che-
lator-bound from chelator-free LPI; reported results are
from chelator-free LPI.
Results
Effect of deferasirox on LPI levels
Overall, 247 of 252 recruited patients into the ESCALA-
TOR trial completed 1 yr of treatment. The LPI sub-
group comprised six male and eight female patients with
a mean age of 17.5 yr (range 12–27). All 14 patients had
previously received DFO⁄deferiprone combination ther-
apy for a mean period of 30 months (range 9–44). As
one patient died because of a non-treatment-related
cause (cardiac failure) between weeks 4 and 16, the LPI
data presented are from 13 patients.
At baseline, mean LIC and median serum ferritin levels
were 28.6 ± 10.3 mg Fe⁄g dw (range 11.5–45.2) and
6334 ng⁄mL (range 4537–16 620) respectively. Mean base-
line LPI levels were 0.98 ± 0.82 lmol⁄L (range 0–2.7)
and were signiﬁcantly correlated with LIC (R = 0.63,
P = 0.0198) (Fig. 1). Two hours after deferasirox dosing
at baseline, overall mean LPI levels decreased signiﬁcantly
to 0.12 ± 0.16 lmol⁄L postadministration (P = 0.0006).
A signiﬁcant reduction in LPI from pre- to post-deferasi-
rox was also observed at weeks 4 (P = 0.0129), 16
(P = 0.0269) and 40 (P = 0.0284); the reduction at weeks
28 (P = 0.0544) and 52 (P = 0.1571) was non-signiﬁcant.
There was also a signiﬁcant reduction in preadministration
LPI from baseline to week 4 and week 16, at which point
LPI levels were within the normal range (0–0.4 lmol⁄L)
(Fig. 2). Preadministration LPI levels remained signiﬁ-
cantly lower than baseline and within the normal range at
every subsequent time point throughout the remainder of
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Figure 1 Scatterplot of LPI and LIC at baseline.
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showed a signiﬁcant correlation with LIC (R = 0.55, P =
0.024). During deferasirox treatment, median serum ferri-
tin decreased by )942 ng⁄mL (range )4411 to 893) to
5643 ng⁄mL, while mean (±SD) LIC decreased by
)6.8 ± 6.2 mg Fe⁄g dw (range )14.9 to 3.1) to 21.7 mg
Fe⁄g dw.
Deferasirox pharmacokinetics
Mean steady state plasma concentration (i.e. preadminis-
tration value) of deferasirox at weeks 4, 16, 28, 40 and
52 was 23.1, 47.1, 94.9, 69.5 and 74.4 lmol⁄L respec-
tively (Fig. 3). At each time point, this was approxi-
mately half of the concentration value observed at 2 h
postadministration (68.8, 116.4, 163.5, 132.0 and
146.4 lmol⁄L respectively). Figure 3 highlights the rela-
tionship between deferasirox plasma concentration and
LPI, demonstrating an inverse correlation between pre-
administration LPI levels and trough plasma concentra-
tions where a plateau appears to be reached at week 16.
The deferasirox–iron complex was detectable in the
plasma at each time point, with preadministration values
ranging from 3.7–9.2 lmol⁄L.
Discussion
The results from this 1-yr study highlight the ability of
deferasirox ‡20 mg⁄kg⁄d to provide sustained reduction
in LPI levels. After 4 wk of treatment and throughout
the remainder of the 1-yr treatment period, peak LPI lev-
els observed just before deferasirox dosing were signiﬁ-
cantly decreased compared with baseline; peak LPI levels
were within the normal range (<0.4 lmol⁄L) (3) from
week 16 onwards. This is likely because trough levels of
deferasirox in this trial are within the therapeutic range,
being consistent with those observed in previous trials
involving patients of similar ages who received a compa-
rable drug treatment regimen (unpublished data and
available by request), thereby preventing LPI levels
rebounding between doses. This is in contrast to LPI lev-
els during treatment with other chelators, which have
been shown to rebound as chelation coverage decreases
between doses (3).
Notably, patients in this subgroup had a high baseline
iron burden, despite prior chelation therapy with com-
bined DFO and deferiprone. LIC and serum ferritin lev-
els were markedly higher than thresholds associated with
an increased risk of cardiac complications and early
death (9, 10). Baseline LPI levels were also high, leading
to an increased risk of the production of harmful hydro-
xyl radicals (8). However, in this subgroup of patients,
deferasirox treatment for 1 yr led to reductions in LIC,
serum ferritin and LPI.
One patient died because of cardiac failure 1 month
after study enrolment; this was not considered to be
study drug-related.
In conclusion, once-daily dosing with deferasirox pro-
vided sustained reduction in LPI levels in this subgroup of
heavily iron-overloaded patients from the ESCALATOR
study, suggesting 24-h protection from LPI. Deferasirox
may therefore reduce unregulated tissue iron loading and
prevent further end-organ damage in these patients.
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Figure 3 Relationship between preadministration LPI levels (±SE)
and trough deferasirox plasma concentration.
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